Gene therapy

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights episode: 16 December 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a big week for cell and gene therapies… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (9-13 December) 

News round-up for 9-13 December by DDW Senior Digital Content Editor Diana Spencer. It’s been a big week for cell and gene therapies (CGTs) as the first in vivo BCMA CAR-T candidate reaches the clinic and a new discovery could lead to a gene therapy that reverses a… Read More

#News

#Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Gene therapy positively impacts Duchenne disease trajectory

AFFINITY DUCHENNE, a multi-centre, open-label trial of gene therapy RGX-202 for Duchenne muscular dystrophy has dosed its first patient, REGENXBIO has announced. The company also revealed new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data. Read More

#News

#Career #Gene therapy #Interview #Meet the Researcher

Meet the researcher: Dr Gloria Gonzalez-Aseguinolaza

In July 2024, Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics, received the Rosalind Franklin Society Special Award in Science. DDW’s Diana Spencer caught up with her about her career in gene therapy. DS: Can you tell us what you do and what you’re working on at the moment? … Read More

#Exclusive Content

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Don’t miss out: Last chance to register for the DDW CGT Showcase

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters,… Read More

#News #Regulatory

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Webinar: Overcome the challenges of developing CGTs

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

Gene therapy
#CNS #Financing #Gene therapy #Neurogene #Private investment

Oversubscribed $200m private placement for gene therapy company

Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million. Neurogene is developing approaches and treatments which it hopes will address the limitations of conventional gene therapy in central… Read More

#Business & Investment #News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Register now: Discover areas of opportunity in CGT drug discovery

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

Gene therapy
#Gene editing #Gene therapy #hepatitis #Phase I trial #Precision BioSciences

Precision hopes to cure chronic hepatitis B with gene editing

Precision BioSciences has announced it will commence a Phase I clinical trial for its in vivo gene editing programme PBGENE-HBV, following Clinical Trial Application (CTA) approval in Moldova. PBGENE-HBV is designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B… Read More

#News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

What will the future bring in cell and gene therapies?

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

#AAV #Collaboration #Dyno Therapeutics #Gene therapy #Neurology #Roche

Roche and Dyno advance AAV gene therapies for neurological diseases

Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno… Read More

#Business & Investment #News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Register now for DDW’s Cell & Gene Therapy Showcase

Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges… Read More

#News

Kidneys
#Financing #Gene therapy #Kidney disease #Purespring Therapeutics

Financing to transform the treatment of kidney diseases

Purespring Therapeutics, a gene therapy company focused on the treatment of kidney diseases, has raised £80 ($105) million in Series B financing. The oversubscribed round was led by Sofinnova Partners, in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona. Read More

#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene editing #Gene therapy

Cell & Gene Therapy Showcase

In this free online event leading industry figures outline areas of opportunity in CGT drug discovery and development sector as well as highlighting challenges facing the industry and how they can be overcome. It features presentations from experts in the field of cell and gene therapy drug development as well… Read More

Webinar date:
Co-sponsored by Benchling, Sartorius, Applied StemCell, and Elegen Bio
#Webinars